Court Blocks Mail Access to Abortion Pill

A federal appeals court on Friday temporarily suspended the ability of abortion providers to prescribe medication via telemedicine and deliver it by mail, impacting a significant avenue for abortion access in the United States. The U.S. Court of Appeals for the Fifth Circuit granted Louisiana's request for a temporary stay on the Food and Drug Administration's (FDA) prior decision to remove the in-person consultation requirement for abortion pills.

This ruling stems from a lawsuit filed by the state of Louisiana against the FDA, seeking to restrict access to mifepristone, a key abortion medication. The court cited Louisiana's claim of irreparable harm, noting that mail-order access allowed patients to obtain medication despite the state's near-total abortion ban. Danco Laboratories, a mifepristone manufacturer, has filed a motion requesting a one-week stay of the ruling to prepare an appeal to the U.S. Supreme Court.

The decision could significantly alter the landscape of abortion access, particularly for patients in states with restrictive abortion laws who have relied on shield laws to receive medication by mail. Over 100,000 patients annually in states with abortion bans have accessed pills through this method.

Legal experts suggest the case could lead to a constitutional challenge regarding the enforcement of differing state abortion laws and may elevate abortion as a prominent issue in upcoming elections.